Synbio Tech Inc

Synbio Tech Inc has a liquidity risk profile marked by negative net cash of TWD 1,274,210,000 (computed as cash_and_equivalents - long_term_debt). The company's liquidity_fpt shows a price-to-book ratio of 1.4 and a current ratio of 1.2, indicating moderate short-term liquidity coverage. The free cash flow of -TWD 559,556,000 reflects significant capital outflows, primarily driven by capital expenditures of -TWD 705,013,000. Profitability metrics show a return on equity of 13.23% and return on assets of 5.7%, both above the industry_config median for Food Processing companies. The gross margin of 53.4% (computed as gross_profit / revenue) is strong, but the operating margin of 19.1% (operating_income / revenue) suggests pressure from operating expenses. The company's debt-to-equity ratio of 1.04 indicates moderate leverage, with long-term debt accounting for 45% of total capital (computed as long_term_debt / (total_equity + long_term_debt)). The company's revenue is concentrated in undisclosed segments, with no disclosed geographic breakdown. Given the absence of segment-specific data, it is not possible to assess geographic or product diversification. The company's exposure to lactic acid bacteria applications in human health and animal feed suggests potential for cross-sector demand, but the lack of segment reporting limits visibility into growth drivers. Outlook data shows a revenue growth rate of 0% for the current fiscal year and 0% for the next fiscal year, based on the absence of directional change in revenue figures. The company's net income growth is similarly flat, with a 0% year-over-year change in net_income. Analysts have assigned a mean recommendation of 1.00 (strong buy), but the absence of revenue or EPS growth projections suggests limited visibility into future performance. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's free cash flow is negative, and its net cash position is negative after subtracting total debt. No dilution sources are disclosed in the 10-K or recent filings, and the shares_outstanding_basic and shares_outstanding_diluted are equal, indicating no near-term dilution pressure. Recent events include the publication of the latest financial snapshot and analyst estimates. No material filings or transcripts have been disclosed in the input data. The company's strong analyst recommendation of 1.00 (strong buy) contrasts with its flat revenue and net income growth, suggesting a potential disconnect between market sentiment and operational performance.